EPS: As of FY2025 Q1, the actual value is USD -0.45.<h3>Segment Revenue</h3>Dermata Therapeutics, Inc. did not generate any revenue for the three months ended March 31, 2025, and 2024.<h3>Operational Metrics</h3><ul><li>Net Loss: The company reported a net loss of $2.3 million for the three months ended March 31, 2025, compared to a net loss of $3.1 million for the same period in 2024, showing an improvement of $0.8 million.</li><li>Operating Expenses: Total operating expenses decreased from $3.2 million in 2024 to $2.3 million in 2025, primarily due to reductions in research and development expenses and general and administrative expenses.</li><li>Research and Development: Expenses decreased by $0.3 million, from $1.6 million in 2024 to $1.3 million in 2025.</li><li>General and Administrative: Expenses decreased by $0.5 million, from $1.6 million in 2024 to $1.1 million in 2025.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash used in operating activities was $1.9 million for the three months ended March 31, 2025, compared to $2.7 million for the same period in 2024.</li><li>Financing Activities: The company raised $8.5 million from financing activities during the three months ended March 31, 2025, primarily from the January 2025 PIPE financing and the March 2025 Inducement financing.</li></ul><h3>Unique Metrics</h3><ul><li>Stock-Based Compensation: Total stock-based compensation expense was $37,189 for the three months ended March 31, 2025, compared to $587,234 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Dermata Therapeutics plans to focus on the development, regulatory approval, and potential commercialization of XYNGARI™ for the treatment of acne. The company anticipates incurring net losses for the next several years as it completes clinical development and continues research and development of its product candidates.</li><li>Non-Core Business: The company is exploring opportunities to identify, acquire, or in-license additional drug candidates and potentially build commercial capabilities.</li><li>Priority: The company believes its existing cash and cash equivalents will be sufficient to fund operations into the first quarter of 2026, but it will require additional capital to complete Phase 3 studies for XYNGARI™ and pursue other strategic initiatives.</li></ul>

DERMATA THERAPEUTICS INC C/WTS (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.45